Data on 2 Drugs, Identified Via AI, Shared at Conference
Research Report
AI Breakthroughs Drive New Momentum in Oncology Research
Analyst: Scientific Instrument Co.'s Q3/25 Results 'Soft'
Research Report
Biotech Co. Advances Precision Psychiatry Breakthrough Pipeline While Analysts' Sentiment Remains Positive
Biotech Co.'s Q3/25 Progress on Lead Programs Steady
Research Report
AI Identifies Preclinical Cancer Compounds With Potential to Reach the Brain
Clean Tech Co.: Wound Care Subsidiary Set to Take Off; 3Q Results
US$12 Billion RNA Deal Triggers Sector Shakeup
Avidity Biosciences Inc. (RNA:NASDAQ) reported Q3 results alongside news of its US$12 billion acquisition by Novartis. The deal comes as three RNA drugs approach major regulatory filings through 2026.Preclinical Compounds Perform Better Than Existing Drugs
Research Report
Rakovina Therapeutics Inc.'s (RKV:TSX.V) AI-designed Compounds A, B and C demonstrated the same ATR blocking activity as three of Big Pharma's existing, clinical-stage drugs but at much lower concentrations, noted a Leede Financial Inc. report. Lead Drug Faces Uncertain FDA Path After Phase 3 Miss
aTyr Pharma Inc. (ATYR:NASDAQ) is seeking regulatory clarity following mixed Phase 3 results for its lead candidate efzofitimod in pulmonary sarcoidosis. The company expects feedback from the FDA in the first quarter of 2026 to help determine a potential path forward.Breakthrough Pill Cuts Bad Cholesterol by Nearly 60% in Major Trials
Merck & Co. Inc. (MRK:NYSE) announced that its investigational oral PCSK9 inhibitor, enlicitide, achieved significant LDL-C reductions in two pivotal Phase 3 studies presented at the American Heart Association Scientific Sessions. The once-daily pill demonstrated efficacy comparable to injectable therapies, marking a major step forward in cholesterol management.Biotech to Fast Track Phase 3 Depression Trial
Research Report
Alto Neuroscience Inc. (ANRO:NYSE) intends to carry out this newly added study, supported by a recent financing, and the previously planned Phase 2b trial simultaneously, noted a William Blair report. 2 Key Catalysts Ahead for Developer of Psych Drugs
Research Report
Alto Neuroscience Inc. (ANRO:NYSE) expects to release topline trial data in 2025 and commence a separate study in 2026, noted an H.C. Wainwright & Co. report. Co. Speeds Up Development of New Drug for Depression
Research Report
Alto Neuroscience Inc. (ANRO:NYSE) plans Phases 2b and 3 trials of its asset, ALTO-207, in treatment-resistant depression, noted a Jefferies report. Price Target on Psychiatric Drug Biotech Boosted 200%
Research Report
Alto Neuroscience Inc. (ANRO:NYSE) completed a US$50 million equity raise and announced plans to accelerate development of its recently acquired asset in treatment-resistant depression, noted a Wedbush report. US Biopharma In-Licenses 3 New Assets
Research Report
Zenas BioPharma Inc.'s (ZBIO:NASDAQ) target price is increased 14% to reflect the Phase 3 investigative multiple sclerosis drug included in this recent deal, noted a Wedbush report. 
Streetwise Key Charts
